Amyloid-beta peptide N-terminal epitope (Aβ1-10) (Aβ1-10)

The Amyloid-beta 1-10 N-terminal epitope refers to the first ten amino acids of the amyloid-beta (Aβ) peptide, which is generated through the sequential cleavage of the amyloid precursor protein (APP) by beta- and gamma-secretases (UniProt: P05067). This specific N-terminal sequence is highly exposed in both monomeric and aggregated forms of Aβ, making it a critical target for therapeutic antibodies in Alzheimer's disease (PubMed: 22992331). In the brain, Aβ accumulation into oligomers and fibrils is associated with synaptic dysfunction, neuroinflammation, and neuronal death, which are central to the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy (PubMed: 30675052). Drugs targeting this epitope, such as Bapineuzumab and Aducanumab, work by binding to the N-terminus to facilitate the clearance of amyloid deposits via microglial phagocytosis or by neutralizing toxic soluble species (PubMed: 24450857). While these therapies aim to slow cognitive decline, they are frequently associated with Amyloid-Related Imaging Abnormalities (ARIA), which represent a significant clinical challenge in patient management (PubMed: 28137183).

Other names

Abeta 1-10Aβ(1-10)Amyloid-beta N-terminusAβ N-terminal domain

Passive or active immunotherapy targeting the N-terminus to promote microglial-mediated clearance of amyloid plaques and neutralization of toxic oligomers.